Analyst Price Targets — SNY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 8:31 am | Peter Verdult | BNP Paribas | $50.00 | $48.06 | TheFly | Sanofi downgraded to Neutral from Outperform at BNP Paribas |
| June 2, 2025 10:07 am | Sarita Kapila | Morgan Stanley | $56.00 | $49.19 | TheFly | Sanofi resumed with an Equal Weight at Morgan Stanley |
| September 10, 2024 5:42 am | Luisa Hector | Berenberg Bank | $64.00 | $58.51 | TheFly | Sanofi price target raised to $64 from $56 at Berenberg |
| July 26, 2024 7:33 am | Jasper Hellweg | Argus Research | $60.00 | $52.54 | StreetInsider | Sanofi-Aventis (SNY) PT Raised to $60 at Argus |
| April 3, 2024 12:55 pm | Jasper Hellweg | Argus Research | $55.00 | $48.00 | StreetInsider | Sanofi-Aventis (SNY) PT Lowered to $55 at Argus, 'BUY as FDA reviews Dupixent for COPD' |
| December 21, 2022 1:30 pm | Iain Simpson | Barclays | $48.07 | $48.17 | TheFly | Sanofi confirms to Bloomberg Zantac settlement in California |
Latest News for SNY
On April 23, Sanofi will report its results for the first quarter of 2026. As a reminder, its revenue grew 23.1% year-over-year to $13.53 billion in Q4 last year. Meanwhile, Sanofi's non-GAAP P/E ratio [FWD] is 9.66x, which, in my view, clearly indicates that it is trading at a discount.
Assetmark Inc. boosted its position in Sanofi (NASDAQ: SNY) by 24.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 443,668 shares of the company's stock after purchasing an additional 86,496 shares during the period. Assetmark Inc.'s holdings in
Sanofi (NASDAQ: SNY - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect Sanofi to post earnings of $0.9330 per share and revenue of $10.8086 billion for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the
Top insights from the latest market news from Tuesday, April 14, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SNY.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.